
Suryyani Deb

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5284782/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Pilot Study on Probing of Imatinib Induced Platelet Dysfunction in Patients with Chronic Myeloid Leukemia-Chronic Phase and Absence of Associated Bleeding Manifestation: Trying to Solve an Enigma. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 162-166.	0.6	1
2	Innate Immune Invisible Ultrasmall Gold Nanoparticles—Framework for Synthesis and Evaluation. ACS Applied Materials & Interfaces, 2021, 13, 23410-23422.	8.0	9
3	Platelets in Diagnostic. Studies in Systems, Decision and Control, 2021, , 275-291.	1.0	0
4	Varying effects of tyrosine kinase inhibitors on platelet function—A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?. Cancer Medicine, 2020, 9, 313-323.	2.8	16
5	Probing ADP Induced Aggregation Kinetics During Platelet-Nanoparticle Interactions: Functional Dynamics Analysis to Rationalize Safety and Benefits. Frontiers in Bioengineering and Biotechnology, 2019, 7, 163.	4.1	11
6	Rational Nanotoolbox with Theranostic Potential for Medicated Proâ€Regenerative Corneal Implants. Advanced Functional Materials, 2019, 29, 1903760.	14.9	10
7	Individual Variation in Hemostatic Alterations Caused By Tyrosine Kinase Inhibitors - a Way to Improve Personalized Cancer Therapy?. Blood, 2016, 128, 1908-1908.	1.4	1
8	Nanoimaging in cardiovascular diseases: Current state of the art. Indian Journal of Medical Research, 2015, 141, 285.	1.0	25
9	Surface tunability of nanoparticles in modulating platelet functions. Blood Cells, Molecules, and Diseases, 2012, 48, 36-44.	1.4	38
10	Multistability in platelets and their response to gold nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 376-384.	3.3	74
11	Platelet responsiveness to yohimbine hydrochloride and MRS2179 in the context of the interaction between collagen and epinephrine in acute coronary syndrome. Blood Cells, Molecules, and Diseases, 2009, 43, 105-110.	1.4	8
12	Dual antiplatelet drug resistance in patients with acute coronary syndrome. Indian Heart Journal, 2009, 61, 68-73.	0.5	18
13	Dual antiplatelet therapy in ACS: time-dependent variability in platelet aggregation during the first week. Indian Heart Journal, 2009, 61, 173-7.	0.5	3
14	Antiplatelet drug resistance in patients with recurrent acute coronary syndrome undergoing conservative management. Indian Heart Journal, 2009, 61, 348-52.	0.5	11
15	Role of purinergic receptors in platelet-nanoparticle interactions. Nanotoxicology, 2007, 1, 93-103.	3.0	17